Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced that it was granted two key patents for lead immuno-oncology candidate asunercept in multiple territories. A composition of matter patent protecting the product asunercept and its manufacturing process was already granted in 2016 by the U.S. Patent and Trademark Office. Apogenix has now received the corresponding composition of matter patents in Europe, Japan, Australia, and Russia. The patents are valid through 2033 in these territories.

The company was further granted a method of use patent covering the use of CD95 ligand inhibitors, such as asunercept, to treat patients with low to intermediate-1 risk myelodysplastic syndromes (MDS) in the United States, China, Japan, Australia, and Russia at least until 2033. The corresponding European patent was already granted in 2016. This is the second method of use patent that Apogenix has received for its lead drug candidate asunercept. The company already holds patents covering the medical use of CD95 ligand inhibitors for the treatment of glioblastoma in key territories such as Europe, the United States, Canada, and Japan. These patents are valid at least until 2027.

“Apogenix has a strong patent portfolio protecting its immuno-oncology projects in all leading pharmaceutical markets,” said Thomas Hoeger, Ph.D., CEO of Apogenix. “These new patents expand the IP protection for asunercept even further and are critical in harnessing the medical and economic potential of this innovative drug candidate. We are currently preparing additional clinical trials with asunercept in both glioblastoma and MDS, so patients can benefit from this new therapeutic approach as soon as possible.”

About Asunercept Apogenix’ lead immuno-oncology candidate asunercept is a fully human fusion protein that consists of the extracellular domain of the CD95 receptor and the Fc domain of an IgG1 antibody. It is being developed for the treatment of solid tumors and malignant hematological diseases. Asunercept was granted orphan drug designation for the treatment of glioblastoma and myelodysplastic syndromes (MDS) in both the EU and the US. In 2017, asunercept received PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA) for the treatment of glioblastoma.

[huge_it_slider id=”9″]

See all Apogenix´s patents around the world here –> Appogenix Patent Family

See below all Apogenix´s patents granted in the United States Patent Office (USPTO):

	PAT. NO.		Title
1	10,000,550		GITRL-collectin fusion proteins and encoding nucleic acids
2	9,908,928		Artificial signal peptide
3	9,908,927		Single-chain trail-receptor agonist proteins
4	9,725,495		CD27 single chain molecules and encoding nucleic acids
5	9,657,083		Composition comprising a mixture of CD95-Fc isoforms
6	9,540,431		Inhibitors of the CD95 signaling pathway for treatment of MDS
7	9,527,897		CD40L collectin fusion proteins and encoding nucleic acid molecules
8	9,469,681		Fusion proteins forming trimers
9	9,434,783		Shortened CD95-Fc variant fusion proteins, nucleic acids and host cells thereof
10	9,359,420		Single chain trail fusion polypeptides and encoding nucleic acids
11	9,340,599		Single chain CD40L fusion polypeptides
12	9,315,570		Composition comprising a mixture of CD95-Fc isoforms and methods of producing same
13	9,212,211		Trail collectin fusion proteins
14	8,921,519		Single chain fusion polypeptides comprising soluble light cytokine domains
15	8,907,063		TNF superfamily collectin fusion proteins and encoding nucleic acids
16	8,664,366		Fusion proteins forming trimers
17	8,592,557		Multimeric TNF receptor fusion proteins and nucleic acids encoding same
18	8,580,273		TNF superfamily member light fusion proteins
19	8,450,460		Single-chain TNFSF fusion polypeptides
20	8,383,774		Collectin fusion proteins comprising TNF or trail
21	8,147,843		CD95L or trail fusion proteins
22	8,007,813		CD95-Fc fusion proteins